Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Pulmonary vascular disease for the general respiratory clinician

Brian D. Kent
Breathe 2022 18: 220261; DOI: 10.1183/20734735.0261-2022
Brian D. Kent
1Dept of Respiratory Medicine, St James’ Hospital, Dublin, Ireland
2School of Medicine, Trinity College Dublin, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: briankent@physicians.ie
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Pulmonary vascular disease is relevant to many practising respiratory clinicians: ∼1% of the world's population is estimated to have PH, and it is an important consequence of many other respiratory diseases (e.g. COPD, ILD, sleep breathing disorders) https://bit.ly/3hLqUx1

Coinciding with the recent publication of the updated European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines for the diagnosis and management of pulmonary hypertension (PH) [1], this issue of Breathe focuses on pulmonary vascular disease, from pulmonary arterial hypertension (PAH) to pulmonary vasculitides. Although sometimes considered a rather niche area of respiratory medicine, pulmonary vascular disease is highly relevant to many practising respiratory clinicians: approximately 1% of the world's population is estimated to have PH, and it is an important consequence of many other respiratory diseases, including COPD, interstitial lung disease (ILD) and sleep breathing disorders.

Characterised by the development of pulmonary vasculopathy, with intimal fibrosis, medial hypertrophy, vasoconstriction and thrombosis, PAH (World Health Organization group 1 PH) had been considered a disease that predominantly affected younger women and conferred a particularly grim prognosis [2]. As discussed by Cullivan et al. [3], it is now apparent that PAH is frequently diagnosed in older cohorts and in men, and is an important complication of connective tissue disease, congenital heart disease, and infectious diseases like HIV and schistosomiasis. The treatment of PAH has been transformed in the past two decades by a growing understanding of the physiological and molecular mechanisms underpinning the disease, with five classes of medication targeting different pathways now in use, and helping to dispel any sense of therapeutic nihilism that may have existed around it.

In contrast with PAH, specific therapies for most patients with PH as a consequence of lung disease or hypoxia (group 3 PH) are lacking. For example, phosphodiesterase inhibitors such as sildenafil are important agents in the management of PAH, but in group 3 PH any improvement they deliver in pulmonary haemodynamics is often offset by a worsening in gas exchange and functional status [4]. Krompa and Marino [5] discuss the identification and management of PH in chronic respiratory disease, including how current evidence suggests that care of these patients should be focussed on optimising management of the underlying respiratory disease, including use of oxygen therapy, noninvasive ventilation and pulmonary rehabilitation where appropriate. Meanwhile, recent data regarding the use of treprostinil in ILD patients with PH shows that ongoing trials of therapies specifically targeting the pulmonary vasculature remain worthwhile in patients with group 3 PH.

The bedrocks of management of chronic thromboembolic pulmonary hypertension (CTEPH; group 4 PH) are pharmacotherapy and, in selected patients, surgical pulmonary endarterectomy. However, medical therapy is not always effective in CTEPH patients, and not all patients or pulmonary vascular lesions are suitable for surgical intervention. This issue's “Landmark papers in respiratory medicine” article discusses key studies in the use of balloon pulmonary angioplasty in CTEPH, and how they have changed the management of non-operable disease [6].

PH is an important potential complication of chronic lung disease of prematurity. In a forthcoming article, S. Chan and co-workers outline what paediatric respiratory clinicians should know about PH in children with bronchopulmonary dysplasia, emphasising the importance of the multidisciplinary team in its management.

Not all pulmonary vascular disease involves PH. Pulmonary vasculitides are uncommon, but can be devastating, and may crop up in unexpected places, like the asthma clinic or the ILD clinic. Alam and Nanzer [7] present a review of eosinophilic granulomatosis with polyangiitis (EGPA), including a discussion of how the development of eosinophil-targeting biologic agents has improved outcomes and reduced the burden of systemic corticosteroid therapy in patients with this challenging disease. In a companion article, Boyle et al. [8] discuss the clinical presentation, diagnosis and management of pulmonary renal syndromes, including anti-glomerular basement membrane (GBM) disease and antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis.

In keeping with the overall theme of the issue, our forthcoming Lung function corner discusses the measurement of pulmonary haemodynamics, and we have our usual slate of content for and by our early career members, including an overview of the new ERS Clinical Practice Guidelines Methodology Network [9]. We hope you enjoy this issue of Breathe, and as ever, we would be delighted to hear any feedback or suggestions readers may have for future issues and content.

Footnotes

  • Conflict of interest: B.D. Kent has participated in advisory boards and/or received speaker fees from Astra Zeneca, Chiesi, GSK, Novartis, and Teva; has received educational travel bursaries from Boehringer Ingelheim, Chiesi, and Napp; and has received research funding from Itamar Medical.

  • Received November 11, 2022.
  • Accepted November 11, 2022.
  • Copyright ©ERS 2022
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Humbert M,
    2. Kovacs G,
    3. Hoeper MM, et al.
    2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2022; in press [https://doi.org/10.1183/13993003.00879-2022].
  2. ↵
    1. Lau EMT,
    2. Giannoulatou E,
    3. Celermajer DS, et al.
    Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol 2017; 14: 603–614. doi:10.1038/nrcardio.2017.84
    OpenUrlCrossRefPubMed
  3. ↵
    1. Cullivan S,
    2. Higgins M,
    3. Gaine S
    . Diagnosis and management of pulmonary arterial hypertension. Breathe 2022; 18: 220168. doi:10.1183/20734735.0168-2022
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Blanco I,
    2. Gimeno E,
    3. Munoz PA, et al.
    Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181: 270–278. doi:10.1164/rccm.200907-0988OC
    OpenUrlCrossRefPubMed
  5. ↵
    1. Krompa A,
    2. Marino P
    . Diagnosis and management of pulmonary hypertension related to chronic respiratory disease. Breathe 2022; in press [https://doi.org/10.1183/20734735.0205-2022].
  6. ↵
    1. Jevnikar M,
    2. Bokan A,
    3. Gille T, et al.
    Balloon pulmonary angioplasty: are we there yet? Lessons learned and unanswered questions. Breathe 2022; in press [https://doi.org/10.1183/20734735.0217-2022].
  7. ↵
    1. Alam V,
    2. Nanzer AM
    . Eosinophilic granulomatosis with polyangiitis: case report and literature review. Breathe 2022; 18: 220170. DOI:10.1183/20734735.0170-2022
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Boyle N,
    2. O'Callaghan M,
    3. Ataya A, et al.
    Pulmonary renal syndrome: a clinical review. Breathe 2022; in press [https://doi.org/10.1183/20734735.0208-2022].
  9. ↵
    1. Vaccaro V,
    2. Cruz J
    . Overview of the new ERS Clinical Practice Guidelines Methodology Network. Breathe 2022; 18: 220213. DOI:10.1183/20734735.0213-2022
    OpenUrlFREE Full Text
PreviousNext
Back to top
Vol 18 Issue 4 Table of Contents
Breathe: 18 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pulmonary vascular disease for the general respiratory clinician
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Pulmonary vascular disease for the general respiratory clinician
Brian D. Kent
Breathe Dec 2022, 18 (4) 220261; DOI: 10.1183/20734735.0261-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Pulmonary vascular disease for the general respiratory clinician
Brian D. Kent
Breathe Dec 2022, 18 (4) 220261; DOI: 10.1183/20734735.0261-2022
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Sleep medicine in Europe: 50 years of evolution
  • Managing respiratory disease in pregnancy
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society